Emerging Ulcerative Colitis Treatments
- Limited to Elgibile patients
- 692 Locations
New treatments for Ulcerative Colitis will be widely available in the coming years. Patients who are flaring today and want to try out one of these new treatments may be able to do so through a clinical trial at a local Ulcerative Colitis specialist's clinic. Study medication and medical visits are usually free. Patients are usually compensated for their participation.
These new treatments are expected to be more effective and safer than existing treatments. Some are injections whereas others are pills.
We are happy to discuss the treatment options and available specialists and clinics near you.
You may be eligible to participate if you meet the following criteria:
- Ages 18 - 80
- Male or Female
- Moderately to severely active ulcerative colitis (i.e. not in remission)
How You Can Participate
This study is currently accepting candidates in 692 locations.
Frequently Asked Questions
- How much does it cost?
- The treatment and doctor visits are free.
- Are traveling expenses covered?
- Travel expenses will generally be covered.
Here's a timeline of what you can expect:
Step 1: Online Pre-screener
Find out if you are a match by answering a few online questions.
Stay Informed ›
Step 2: Phone Call with Care Coordinator
Speak with our Care Team specialist to confirm your candidacy.
Step 3: Screening Appointment
If you are eligible to continue, you will be given an appointment date and time to come to the clinic for a screening visit.
Other Emerging Treatments
Etrolizumab for Ulcerative Colitis (TNF Inhibitors Naive)
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have not tried an anti-TNF therapy (e.g. Remicade, Humira, etc.).
Etrolizumab for Ulcerative Colitis (For patients who have previously used anti-TNFs)
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have failed an anti-TNF therapy (e.g. Remicade, Humira, etc.) previously.
Vedolizumab for Pouchitis
Vedolizumab is an intraveneous medication for ulcerative colitis who have had bowel surgery involving a proctocolectomy and ileal pouch anal anastomosis.